Therefore, in this study, we first aimed to compare the clinical characteristics and prognosis between HER2‐zero and HER2‐low BC based on the prospective Tianjin Breast Cancer Cases Cohort (TBCCC). This evidence concerns the gene ERBB2 and breast cancer.